使用免疫检查点抑制剂和酪氨酸激酶抑制剂联合治疗转移性非透明细胞肾细胞癌的疗效。

IF 1.9 4区医学 Q3 UROLOGY & NEPHROLOGY

Cuaj-Canadian Urological Association Journal Pub Date : 2024-05-01 DOI:10.5489/cuaj.8548

Jun Teishima, Takuto Hara, Taisuke Tobe, Junichiro Hirata, Hideto Ueki, Naoto Wakita, Yusuke Shiraishi, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Junya Furukawa, Ken-Ichi Harada, Yuzo Nakano, Masato Fujisawa

{"title":"使用免疫检查点抑制剂和酪氨酸激酶抑制剂联合治疗转移性非透明细胞肾细胞癌的疗效。","authors":"Jun Teishima, Takuto Hara, Taisuke Tobe, Junichiro Hirata, Hideto Ueki, Naoto Wakita, Yusuke Shiraishi, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Junya Furukawa, Ken-Ichi Harada, Yuzo Nakano, Masato Fujisawa","doi":"10.5489/cuaj.8548","DOIUrl":null,"url":null,"abstract":"Introduction: We aimed to clarify the therapeutic outcome of combination therapy using immune-checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs) for meta-static non-clear-cell renal cell carcinoma (nccRCC).Methods: We have been retrospectively investigating the therapeutic efficacy and prognosis in 36 patients with metastatic nccRCC undergoing combination therapy using two ICIs, ipilimumab plus nivolumab (ICI-ICI), and ICI plus TKI (ICI-TKI), at Kobe University and affiliated institutions since 2018. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse event (AE) were compared.Results: The first-line regimen was ICI-ICI in 26 cases and ICI-TKI in 10 cases. The ORRs in the ICI-ICI and ICI-TKI groups were 34.6 and 30.0%, respectively (p=0.9433). The 50% PFS for the ICI-TKI group was 9.7 months, significantly longer than that for the ICI-ICI group (4.6 months, p=0.0499), and there was no significant difference in OS between groups (p=0.3984). There was no significant difference in the occurrence rate of AE for below grade 2 (p=0.8535), nor above grade 3 (p=0.3786) between the ICI-ICI and ICI-TKI groups.Conclusions: From our analysis of real-world data, a better outcome of PFS was expected in the ICI-TKI group compared with that in the ICI-ICI group, while there was no significant difference in OS or ORR.","PeriodicalId":50613,"journal":{"name":"Cuaj-Canadian Urological Association Journal","volume":" ","pages":"E162-E166"},"PeriodicalIF":1.9000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11152592/pdf/","citationCount":"0","resultStr":"{\"title\":\"Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinoma.\",\"authors\":\"Jun Teishima, Takuto Hara, Taisuke Tobe, Junichiro Hirata, Hideto Ueki, Naoto Wakita, Yusuke Shiraishi, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Junya Furukawa, Ken-Ichi Harada, Yuzo Nakano, Masato Fujisawa\",\"doi\":\"10.5489/cuaj.8548\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: We aimed to clarify the therapeutic outcome of combination therapy using immune-checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs) for meta-static non-clear-cell renal cell carcinoma (nccRCC).Methods: We have been retrospectively investigating the therapeutic efficacy and prognosis in 36 patients with metastatic nccRCC undergoing combination therapy using two ICIs, ipilimumab plus nivolumab (ICI-ICI), and ICI plus TKI (ICI-TKI), at Kobe University and affiliated institutions since 2018. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse event (AE) were compared.Results: The first-line regimen was ICI-ICI in 26 cases and ICI-TKI in 10 cases. The ORRs in the ICI-ICI and ICI-TKI groups were 34.6 and 30.0%, respectively (p=0.9433). The 50% PFS for the ICI-TKI group was 9.7 months, significantly longer than that for the ICI-ICI group (4.6 months, p=0.0499), and there was no significant difference in OS between groups (p=0.3984). There was no significant difference in the occurrence rate of AE for below grade 2 (p=0.8535), nor above grade 3 (p=0.3786) between the ICI-ICI and ICI-TKI groups.Conclusions: From our analysis of real-world data, a better outcome of PFS was expected in the ICI-TKI group compared with that in the ICI-ICI group, while there was no significant difference in OS or ORR.\",\"PeriodicalId\":50613,\"journal\":{\"name\":\"Cuaj-Canadian Urological Association Journal\",\"volume\":\" \",\"pages\":\"E162-E166\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11152592/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cuaj-Canadian Urological Association Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5489/cuaj.8548\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cuaj-Canadian Urological Association Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5489/cuaj.8548","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

简介：我们旨在阐明使用免疫检查点抑制剂（ICIs）和/或酪氨酸激酶抑制剂（TKIs）联合治疗转移性非透明细胞肾细胞癌（nccRCC）的疗效：自2018年起，我们在神户大学及附属机构对36例接受两种ICIs（伊匹单抗加尼伐单抗（ICI-ICI）和ICI加TKI（ICI-TKI））联合治疗的转移性nccRCC患者的疗效和预后进行了回顾性研究。比较了无进展生存期（PFS）、总生存期（OS）、客观应答率（ORR）和不良事件（AE）：26例一线方案为ICI-ICI方案，10例为ICI-TKI方案。ICI-ICI组和ICI-TKI组的ORR分别为34.6%和30.0%（P=0.9433）。ICI-TKI组50%的PFS为9.7个月，明显长于ICI-ICI组（4.6个月，P=0.0499），两者的OS无明显差异（P=0.3984）。ICI-ICI组和ICITKI组的AE发生率在2级以下（p=0.8535）和3级以上（p=0.3786）无明显差异：从我们对真实世界数据的分析来看，与 ICI-ICI 组相比，ICI-TKI 组的 PFS 预期会更好，而 OS 或 ORR 则无明显差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinoma.

Introduction: We aimed to clarify the therapeutic outcome of combination therapy using immune-checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs) for meta-static non-clear-cell renal cell carcinoma (nccRCC).

Methods: We have been retrospectively investigating the therapeutic efficacy and prognosis in 36 patients with metastatic nccRCC undergoing combination therapy using two ICIs, ipilimumab plus nivolumab (ICI-ICI), and ICI plus TKI (ICI-TKI), at Kobe University and affiliated institutions since 2018. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse event (AE) were compared.

Results: The first-line regimen was ICI-ICI in 26 cases and ICI-TKI in 10 cases. The ORRs in the ICI-ICI and ICI-TKI groups were 34.6 and 30.0%, respectively (p=0.9433). The 50% PFS for the ICI-TKI group was 9.7 months, significantly longer than that for the ICI-ICI group (4.6 months, p=0.0499), and there was no significant difference in OS between groups (p=0.3984). There was no significant difference in the occurrence rate of AE for below grade 2 (p=0.8535), nor above grade 3 (p=0.3786) between the ICI-ICI and ICI-TKI groups.

Conclusions: From our analysis of real-world data, a better outcome of PFS was expected in the ICI-TKI group compared with that in the ICI-ICI group, while there was no significant difference in OS or ORR.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cuaj-Canadian Urological Association Journal 医学-泌尿学与肾脏学

CiteScore

2.80

自引率

10.50%

发文量

167

审稿时长

>12 weeks

期刊介绍： CUAJ is a a peer-reviewed, open-access journal devoted to promoting the highest standard of urological patient care through the publication of timely, relevant, evidence-based research and advocacy information.